Eyeworld

MAY 2018

EyeWorld is the official news magazine of the American Society of Cataract & Refractive Surgery.

Issue link: https://digital.eyeworld.org/i/978371

Contents of this Issue

Navigation

Page 35 of 86

33 EW GLAUCOMA May 2018 Contact information Kammerdiener: lkammerdiener@gmail.com Sharpe: Sharpera@musc.edu Editors' note: Dr. Kammerdiener and Dr. Sharpe have no financial interests related to their comments. Reference 1. Sharpe RA, et al. Efficacy of selective laser trabeculoplasty following incisional glaucoma surgery. Int J Ophthalmol. 2018;11:71–76. because these are already difficult patients who have failed multiple treatments," he said, adding that to have more than one-fourth of all of the patients who had prior incision- al surgery have a positive result was encouraging. Those with higher initial pressures were attaining closer to 20% pressure drops, Dr. Sharpe said. "That made us think that this was an even more powerful tool for those patients who you would oth- erwise rush to put on the schedule for surgery," he said. "Those are the ones who you can buy more time for with SLT." From a clinical perspective, this could bring important change, Dr. Sharpe thinks. "Traditionally the algorithm is to try drops, then at some point the laser becomes an option. If that doesn't work, then you perform an incisional glaucoma surgery. The traditional thinking is that SLT at that point has been sur- passed, and you can't go back and use it," he said. "What we found is that SLT now may have an addition- al role even after glaucoma surgery." Practitioners can bring it back in as a treatment option, just as they would bring in other drops for uncon- trolled pressure in patients who've had surgery, he said. Dr. Kammerdiener likewise views this as a chance to expand the role of SLT, which she thinks has been largely forgotten in post-inci- sional glaucoma patients. "A lot of people think that by the time it has gotten to the level of a trab or tube that they have given up on the out- flow system and at that point they're in the glaucoma surgeon's realm," Dr. Kammerdiener said. "I think that this shows that 25–30% of people can benefit for an extended period of time from having an additional treatment. This should give compre- hensive doctors confidence that if they have a patient who has family issues or something else going on and they need to temporize, this is a possibility. It expands the options for treatment," she concluded. EW

Articles in this issue

Links on this page

Archives of this issue

view archives of Eyeworld - MAY 2018